Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech company developing allogeneic gamma delta T cell therapies, has appointed Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. Dr. Klickstein brings over two decades of leadership experience in biopharma and biomedical research, currently serving as CEO of Koslapp Therapeutics. His expertise in rheumatology, immunology, and drug development, along with his previous role as Chief Innovation Officer at Adicet, is expected to be valuable as the company advances its autoimmune programs and pipeline of gamma delta CAR T therapies. Dr. Klickstein's background includes co-founding Versanis Bio, leadership positions at Novartis, and academic roles at Brigham and Women's Hospital.
Adicet Bio (Nasdaq: ACET), un'azienda biotech in fase clinica che sviluppa terapie con cellule T gamma delta allogeniche, ha nominato Lloyd Klickstein, M.D., Ph.D. nel suo Consiglio di Amministrazione. Il Dr. Klickstein porta oltre due decenni di esperienza di leadership nel biopharma e nella ricerca biomedica, attualmente ricoprendo il ruolo di CEO di Koslapp Therapeutics. La sua esperienza in reumatologia, immunologia e sviluppo farmaceutico, insieme al suo precedente ruolo di Chief Innovation Officer in Adicet, è considerata preziosa mentre l'azienda avanza nei suoi programmi autoimmune e nella pipeline di terapie CAR T gamma delta. Il background del Dr. Klickstein include la co-fondazione di Versanis Bio, posizioni di leadership in Novartis e ruoli accademici presso il Brigham and Women's Hospital.
Adicet Bio (Nasdaq: ACET), una empresa biofarmacéutica en etapa clínica que desarrolla terapias con células T gamma delta alogénicas, ha nombrado a Lloyd Klickstein, M.D., Ph.D. en su Junta Directiva. El Dr. Klickstein aporta más de dos décadas de experiencia en liderazgo en biopharma e investigación biomédica, actualmente ejerciendo como CEO de Koslapp Therapeutics. Su experiencia en reumatología, inmunología y desarrollo de medicamentos, junto con su anterior puesto como Chief Innovation Officer en Adicet, se espera que sea valiosa mientras la empresa avanza en sus programas autoinmunes y en la cartera de terapias CAR T gamma delta. El historial del Dr. Klickstein incluye ser cofundador de Versanis Bio, haber ocupado posiciones de liderazgo en Novartis y roles académicos en el Brigham and Women's Hospital.
Adicet Bio (Nasdaq: ACET)는 동종 유래 감마 델타 T 세포 치료제를 개발하는 임상 단계의 생명공학 회사로, 이사회에 Lloyd Klickstein, M.D., Ph.D.를 임명했습니다. Klickstein 박사는 생명공학 및 생물의학 연구 분야에서 20년 이상의 리더십 경험을 가지고 있으며, 현재 Koslapp Therapeutics의 CEO로 재직 중입니다. 류마티스학, 면역학 및 의약품 개발 분야의 전문 지식이 있으며, Adicet의 Chief Innovation Officer로서의 이전 역할도 있으므로, 회사가 자가면역 프로그램 및 감마 델타 CAR T 치료제 파이프라인을 발전시키는 데 큰 도움이 될 것으로 기대됩니다. Klickstein 박사는 Versanis Bio의 공동 창립, Novartis의 리더십 직책, Brigham and Women's Hospital의 학술 역할을 포함한 경력을 보유하고 있습니다.
Adicet Bio (Nasdaq: ACET), une entreprise biopharmaceutique en phase clinique développant des thérapies par cellules T gamma delta allogéniques, a nommé Lloyd Klickstein, M.D., Ph.D. à son Conseil d'Administration. Le Dr Klickstein apporte plus de vingt ans d'expérience en leadership dans le biopharma et la recherche biomédicale, exerçant actuellement en tant que PDG de Koslapp Therapeutics. Son expertise en rhumatologie, immunologie et développement de médicaments, ainsi que son précédent rôle de Chief Innovation Officer chez Adicet, devraient s'avérer précieux alors que l'entreprise fait progresser ses programmes auto-immuns et son pipeline de thérapies CAR T gamma delta. Le parcours du Dr Klickstein inclut la co-fondation de Versanis Bio, des postes de direction chez Novartis et des rôles académiques à l'hôpital Brigham and Women's.
Adicet Bio (Nasdaq: ACET), ein biopharmazeutisches Unternehmen in der klinischen Phase, das allogene gamma delta T-Zelltherapien entwickelt, hat Lloyd Klickstein, M.D., Ph.D. in seinen Vorstand berufen. Dr. Klickstein bringt über zwei Jahrzehnte Führungserfahrung in der Biopharma- und biomedizinischen Forschung mit und ist derzeit CEO von Koslapp Therapeutics. Seine Expertise in der Rheumatologie, Immunologie und Arzneimittelentwicklung, zusammen mit seiner vorherigen Rolle als Chief Innovation Officer bei Adicet, wird als wertvoll erachtet, während das Unternehmen seine Autoimmunprogramme und seine Pipeline von gamma delta CAR T-Therapien vorantreibt. Der Hintergrund von Dr. Klickstein umfasst die Mitbegründung von Versanis Bio, Führungspositionen bei Novartis und akademische Rollen am Brigham and Women's Hospital.
- Appointment of an experienced industry leader to the Board of Directors
- New board member has specific expertise in Adicet's focus areas: rheumatology, immunology, and gamma delta T cell platform
- Dr. Klickstein's drug development experience could potentially accelerate Adicet's pipeline progress
- None.
“We are pleased to welcome Dr. Klickstein to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Dr. Klickstein’s expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I look forward to working with Lloyd and to his contributions to our board and pipeline of differentiated gamma delta CAR T therapies.”
“Leveraging its proprietary gamma delta T cell platform, Adicet has the potential to develop groundbreaking therapies for autoimmune and oncology indications. I am pleased to join the Board of Directors at Adicet,” said Dr. Klickstein. “I look forward to collaborating with my esteemed colleagues on the board and the management team to drive Adicet's mission of delivering best-in-class gamma delta cell therapies to patients in need.”
Dr. Klickstein has over two decades of leadership experience in the biopharmaceutical industry and biomedical research. He currently serves as President and Chief Executive Officer of Koslapp Therapeutics, Inc. and is the Board Chair of the Lupus Foundation of New England. Dr. Klickstein co-founded Versanis Bio, Inc., where he held multiple executive roles, prior to the Company’s acquisition by Eli Lilly and Co. Before that, he held positions of Chief Innovation Officer at Adicet, Chief Scientific Officer at resTORbio, Inc. (Adicet’s predecessor company) and served as an independent board member at Blade Therapeutics, Inc. Prior to that, Dr. Klickstein was the Global Head of Translational Medicine for the New Indication Discovery Unit and the Exploratory Disease Area at Novartis Institutes for Biomedical Research, overseeing the development of innovative programs across various therapeutic areas. Previously, he was an academic physician-scientist at Brigham and Women’s Hospital (BWH). Dr. Klickstein holds a B.S. from Tufts University and an M.D. and Ph.D. from Harvard University. He completed post-graduate clinical training in Internal Medicine, Rheumatology & Immunology at BWH and a post-doctoral research fellowship at the Center for Blood Research in
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit the Company’s website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: Adicet’s expected growth as a company; Adicet’s plans and expectations for advancing its autoimmune programs across multiple indications; Adicet’s potential to develop best-in-class therapies for autoimmune and oncology indications; and the anticipated contribution of the members of Adicet’s Board of Directors to the Company’s business.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819541077/en/
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
Janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
Who is Lloyd Klickstein, and why was he appointed to Adicet Bio's Board of Directors?
What is Adicet Bio's (ACET) main focus in drug development?
How might Dr. Klickstein's appointment impact Adicet Bio's (ACET) development of autoimmune therapies?
What is Dr. Lloyd Klickstein's current role outside of Adicet Bio (ACET)?
